Associate Director for Clinical Research and the Director of Clinical Research for the MedStar Health Cancer Network’s Washington Region
Oncology
Giuseppe Giaccone
|
|
Give Review
Giuseppe Giaccone is an expert in the field of Oncology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Giuseppe Giaccone is also a published physician. He has 99 publication published. The most recent publication is: Measles inclusion-body encephalitis: Neuronal phosphorylated tau protein is present in the biopsy but not in the autoptic specimens of the same patient. Giuseppe Giaccone accepts all Medicare patients.
Publications
- Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
- Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling.
- Measles inclusion-body encephalitis: Neuronal phosphorylated tau protein is present in the biopsy but not in the autoptic specimens of the same patient.
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
- Mirror Image of the Amyloid-beta Species in Cerebrospinal Fluid and Cerebral Amyloid in Alzheimer's Disease.
- The Existence of Primary Age-Related Tauopathy Suggests that not all the Cases with Early Braak Stages of Neurofibrillary Pathology are Alzheimer's Disease.
- Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer.
- Why has active immunotherapy not worked in lung cancer?
- Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
- A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia.
- Reply to A. Stenzinger et al.
- Refining the treatment of NSCLC according to histological and molecular subtypes.
- Next-Generation Sequencing: Targeting Targeted Therapies.
- The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.
- Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy.
- Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or ...
- Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of t...
- Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States.
- High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
- Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection.
- Response to: intrapulmonary lymph node retrieval.
- Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
- HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
- Panencephalopathic Creutzfeldt-Jakob disease with distinct pattern of prion protein deposition in a patient with D178N mutation and homozygosity for valine at codon 12...
- Idiopathic progressive chorea: misnomer or still reality? A case with neuropathological disconfirmation.
- Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.
- Up-regulation of beta-amyloidogenesis in neuron-like human cells by both 24- and 27-hydroxycholesterol: protective effect of N-acetyl-cysteine.
- Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
- Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
- CYB5A and autophagy-mediated cell death in pancreatic cancer.
- A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cel...
- Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.
- Emerging protein kinase inhibitors for non-small cell lung cancer.
- Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
- Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
- Lung cancer in 2013: Refining standard practice and admitting uncertainty.
- Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma.
- Thymomas: the need for prospective studies.
- Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.
- Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
- Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.
- A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.
- The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.
- The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo.
- Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
- Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
- Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy.
- Globular glial tauopathies (GGT): consensus recommendations.
- A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled t...
- Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, Int...
- Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
- Hereditary and sporadic beta-amyloidoses.
- Severe microcephaly with polynodular heterotopia: a high-field MRI and neuropathological case study.
- Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of In...
- Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.
- Whole genome and transcriptome sequencing of a B3 thymoma.
- "Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
- Dacomitinib , a new therapy for the treatment of non-small cell lung cancer.
- Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.
- Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples.
- Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.
- Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
- 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.
- Tyrosine kinase inhibitors in lung cancer.
- EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
- Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
- NUT rearrangement is uncommon in human thymic epithelial tumors.
- Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.
- Thymic malignancies: from clinical management to targeted therapies.
- Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
- Lung cancer vaccines.
- Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
- Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.
- Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
- A novel phenotype of sporadic Creutzfeldt-Jakob disease.
- Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
- Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
- Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report.
- Met amplification and HSP90 inhibitors.
- Treatment of advanced thymoma and thymic carcinoma.
- The behavioural features of fatal familial insomnia: A new Italian case with pathological verification.
- Next generation oncology drug development: opportunities and challenges.
- Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
- Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combi...
- Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
- Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.
- A novel insertional mutation in the prion protein gene: clinical and bio-molecular findings.
- Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease sm...
- Late presentation of leucoencephalopathy with calcifications and cysts: report of two cases.
- Histone deacetylase inhibitors in cancer therapy.
- Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
- Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
- Newer opportunities in systemic therapy of lung cancer.
- Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium.
- A new function of microtubule-associated protein tau: involvement in chromosome stability.
- Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Doctors Specialties
- Internal Medicine
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Torino Faculty of Medicine
Drug Facts
| NPI NUMBER | 1417193376 | |
| NPPES Provider LastName | GIACCONE | |
| NPPES Provider FirstName | GIUSEPPE | |
| NPPES Provider ZIPCode | 208920001 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 13.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417193376 |
| Last Name Of The Provider | GIACCONE |
| First Name Of The Provider | GIUSEPPE |
| View All |
Similar Doctors
|
|
Dr. Kieron M. Dunleavy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alain Thibault, MD |
|
|
Dr. Stanley Lipkowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian S. Hinrichs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Gulley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee J. Helman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Lechleider, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexandra L. Singer, MD |